Share Fund
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
| Scheme Class | Equity |
| Scheme Category | Sector - Healthcare |
| Expense Ratio | 1.73% |
| Min subscription | ₹ 5,000 |
| Scheme Type | Open-ended |
| Scheme AUM (in Crs.) | ₹ 459 |
| AMC AUM (in Crs.) | ₹ 1,59,694 |
| Min Addition Subscription | ₹ 1,000 |
| Benchmark Type | S&P BSE Healthcare PR |
| Exit Load | Exit load of 1.0%, if redeemed between (0-1) years. No Exit load, if redeemed after 1 years. |
| Fund | Min SIP Inv. | Min Inv. | Returns 3Y |
|---|---|---|---|
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 5.46% |
SBI Healthcare Opportunities Fund - Direct Plan | 0 | 0 | 5.46% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 13.53% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 8.32% |
Nippon India Pharma Fund - Direct Plan | 1000 | 1000 | 13.53% |
UTI Healthcare Fund - Direct Plan | 0 | 0 | 8.32% |
| Company | Holding Type | Asset(%) |
|---|---|---|
Cipla Ltd | Equity | 9 |
Dr Reddy's Laboratories Ltd | Equity | 9 |
Sun Pharmaceuticals Industries Ltd | Equity | 8 |
Aurobindo Pharma Ltd | Equity | 7 |
Lupin Ltd | Equity | 7 |
Divi's Laboratories Ltd | Equity | 6 |
Cadila Healthcare Ltd | Equity | 6 |
Biocon Ltd | Equity | 6 |
Ipca Laboratories Ltd | Equity | 5 |
Ajanta Pharma Ltd | Equity | 5 |
| Asset | Percent |
|---|---|
Equity | 98 |
Other Assets And Liabilities | 2 |
| Sector | Percent |
|---|---|
Healthcare | 97 |
Other Assets And Liabilities | 2 |
Basic Materials | 1 |
Equity | 0 |
Fund Manager
V Srivatsa
3+ years of experience
About
service@uti.co.in
Phone
1800 26 61230
Address
UTI Tower , `GN' Block,,Bandra Kurla Complex,,Bandra (E), Mumbai - 400 051
